Skip to main content
SpringerLink
Log in

Liver disease

Pioneering the path to NASH biomarker approval

  • News & Views
  • Published:

From Nature Medicine

View current issue Submit your manuscript

Despite an urgent need, approved and clinically usable biomarkers for non-alcoholic steatohepatitis (NASH) remain elusive — but a new study moves the field closer to this goal.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1: The path to NASH biomarker development.

References

  1. Sanyal, A. J. et al. Nat. Med. https://doi.org/10.1038/s41591-023-02539-6 (2023).

  2. Rinella, M. E. et al. J. Hepatol. https://doi.org/10.1016/j.jhep.2023.06.003 (2023).

    Article  PubMed  Google Scholar 

  3. Rinella, M. E. et al. Ann. Hepatol. https://doi.org/10.1016/j.aohep.2023.101133 (2023).

    Article  PubMed  Google Scholar 

  4. Rinella, M. E. et al. Hepatology https://doi.org/10.1097/HEP.000000000000052 (2023).

    Article  PubMed  Google Scholar 

  5. Noureddin, M. et al. Am. J. Gastroenterol. 113, 1649–1659 (2018).

    Article  PubMed  PubMed Central  Google Scholar 

  6. Wong, R. J. & Singal, A. K. JAMA Netw. Open. 3, e1920294 (2020).

    Article  PubMed  Google Scholar 

  7. Younossi, Z. M. et al. Clin. Gastroenterol. Hepatol. 19, 580–589.e5 (2021).

    Article  PubMed  Google Scholar 

  8. Vali, Y. et al. Lancet Gastroenterol. Hepatol. 8, 714–725 (2023).

    Article  PubMed  Google Scholar 

  9. Davison, B. A. et al. J. Hepatol. 73, 1322–1332 (2020).

    Article  CAS  PubMed  Google Scholar 

  10. Sanyal, A. J. et al. Hepatology 70, 1913–1927 (2019).

    Article  CAS  PubMed  Google Scholar 

  11. Rasmussen, D. G. K. et al. J. Hepatol. 78, 852–865 (2023).

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Centre for Liver Research, Department of Gastroenterology and Hepatology, Odense University Hospital, Odense, Denmark

    Aleksander Krag

  2. Institute of Clinical Research, University of Southern Denmark, Odense, Denmark

    Aleksander Krag

  3. University of Chicago, Pritzker School of Medicine, Chicago, IL, USA

    Mary E. Rinella

Authors
  1. Aleksander Krag
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mary E. Rinella
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Aleksander Krag.

Ethics declarations

Competing interests

A.K. has served as speaker for Novo Nordisk, Norgine, Siemens and Nordic Bioscience; and participated in advisory boards for Norgine, Siemens, Resalis Therapeutics, Boehringer Ingelheim and Novo Nordisk, all outside the submitted work. A.K. acknowledges research support from Norgine, Siemens, Nordic Bioscience, Astra, Echosens. Consulting Takeda, Resalis Therapeutics, Zealand Pharma, Novo Nordisk and Boehringer Ingelheim; and is a board member and co-founder of Evido. M.E.R. serves as a scientific consultant to Novo Nordisk, Boehringer Ingelheim, Intercept, CytoDyne, Histoindex, NGM Bio, GSK and Madrigal.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Krag, A., Rinella, M.E. Pioneering the path to NASH biomarker approval. Nat Med 29, 2416–2417 (2023). https://doi.org/10.1038/s41591-023-02527-w

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41591-023-02527-w

  • Springer Nature America, Inc.

Search

Navigation